Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | F7 | P08709 | 1/20 | 0.35 |
| ▸ | F3 | P13726 | 1/20 | 0.35 |
| ▸ | FABP3 | P05413 | 5/20 | 0.34 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.34 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29407379 | 0.79 | TSHR (0.50) | TSHRALDH1A1F7F3 | |
| SCHEMBL2373190 | 0.79 | TSHR (0.50) | TSHRALDH1A1F7F3 | |
| SCHEMBL128203 | 0.77 | — | — | |
| SCHEMBL4091375 | 0.75 | — | — | |
| SCHEMBL129431 | 0.75 | F7 (0.43) | TSHRFAAHF7F3 | |
| SCHEMBL4449495 | 0.74 | PPARG (0.54) | TSHRFAAHF7F3 | |
| SCHEMBL2359177 | 0.74 | FABP3 (0.56) | FAAHF7F3FABP3 | |
| SCHEMBL3330873 | 0.73 | TRPA1 (0.52) | FAAHF7F3 | |
| SCHEMBL6422980 | 0.73 | — | — | |
| Ethylene SCHEMBL28334444 | 0.72 | TSHR (0.58) | TSHRALDH1A1FAAHF7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 555 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740171-B1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-06-09 | — | — | EP | claimed |
| US-20070208004-A1 | Indol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-09-06 | — | — | US | claimed |
| EP-1740171-A1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2007-01-10 | — | — | EP | claimed |
| WO-2005094816-A1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-10-13 | — | — | WO | claimed |
| EP-4373493-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH ENHANCED IMID ACTIVITY | Nurix Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-4370123-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH DIMINISHED IMID ACTIVITY | Nurix Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024086296-A1 | COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K | MEKANISTIC THERAPEUTICS LLC (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20240124475-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| US-20240092766-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2024-03-21 | — | — | US | disclosed |
| EP-4334302-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11918569-B2 | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same | POXEL SA (FR) | 2024-03-05 | — | — | US | disclosed |
| US-11905287-B2 | 4-substitued cytisine analogues | THE UNIVERSITY OF BRISTOL (GB) | 2024-02-20 | — | — | US | disclosed |
| US-20070043023-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| WO-2007022459-A2 | PROCESSES AND INTERMEDIATES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007016589-A2 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-02-08 | — | — | WO | disclosed |
| EP-1740171-A1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006127588-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006105035-A2 | MUSCARINIC MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2005094816-A1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-10-13 | — | — | WO | disclosed |
| US-4863947-A | PESTICIDES, INSECTICIDES | ROHM AND HAAS (US) | 1989-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092766-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | TSHR 2748/4885ALDH1A1 1961/4885HPGD 1644/4885 |
| US-20070208004-A1 | Indol-1-yl-acetic acid derivatives | IDO1, IDO2, AANAT | TSHR 3401/4885ALDH1A1 67/4885HPGD 790/4885 |
| US-20240124475-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | TSHR 4040/4885ALDH1A1 4160/4885HPGD 3787/4885 |
| US-11918569-B2 | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same | SLC5A2, PPARD, DPP4 | TSHR 421/4885ALDH1A1 1258/4885HPGD 422/4885 |
| US-11905287-B2 | 4-substitued cytisine analogues | CES2, CDA, PCYT1A | TSHR 2201/4885ALDH1A1 1941/4885HPGD 2597/4885 |
| US-20070043023-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | TSHR 131/4885ALDH1A1 2356/4885HPGD 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.